 Anemia in patients on hemodialysis HD is common and although usually responds well to treatment with Erythropoiesis Stimulating Agents ESAs , this dosage , based on different clinical protocols , often ignores the high variability inter- and intra -individual in patient response . The result leads to swings in the objective by different dosage range that is associated with multiple risks and side effects. There are artificial intelligence-based optimization methods that predict treatment with ESAs in maintaining patient hemoglobin target range . So far the model has been validated for the long half-life of EPO darbepoetin with promising results. 